Registry for pancreatic cancer treatment outcomes using irreversible electroporation
AHPBA Pancreatic Irreversible Electroporation (IRE) Registry for Pancreatic Cancer
This study is creating a registry to see how well irreversible electroporation treatment works for people with pancreatic cancer and to track any side effects they might have.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Louisville Academic / other |
| Locations | 16 sites (Birmingham, Alabama and 15 other locations) |
| Trial ID | NCT02674100 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a comprehensive registry to gather clinical and pathological data on patients with pancreatic cancer undergoing irreversible electroporation (IRE) treatment. By collecting insights on treatment selection and outcomes, the study seeks to establish an evidence base that can guide physicians in providing optimal care for patients requiring surgical interventions. The registry will also track adverse events and complications associated with IRE treatment to enhance understanding of its safety and efficacy.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with pancreatic cancer who are eligible for soft tissue ablation.
Not a fit: Patients with cardiac pacemakers, non-removable metal implants near the target lesion, or those unsuitable for general anesthesia may not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could improve treatment strategies and outcomes for patients with pancreatic cancer.
How similar studies have performed: Other studies involving registries for cancer treatments have shown success in improving patient outcomes and treatment protocols, indicating that this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (greater than 18 years of age) diagnosed with pancreatic cancer that are eligible for soft tissue ablation per the treating physician. Exclusion Criteria: * Have a cardiac pacemaker or ICD implant * Non-removable implants with metal parts near target lesion * Myocardial infarction within 3 months prior to enrollment * Not suitable for general endotracheal anesthesia
Where this trial is running
Birmingham, Alabama and 15 other locations
- University of Alabama Birmingham — Birmingham, Alabama, United States (Recruiting)
- University of California San Diego — San Diego, California, United States (Recruiting)
- University of Colorado — Denver, Colorado, United States (Recruiting)
- University of South Florida — Tampa, Florida, United States (Recruiting)
- Augusta University — Augusta, Georgia, United States (Recruiting)
- University of Louisville — Louisville, Kentucky, United States (Recruiting)
- Johns Hopkins Hospital — Baltimore, Maryland, United States (Recruiting)
- Atlantic Health — Millburn, New Jersey, United States (Recruiting)
- Northwell Health Cancer Institute — Lake Success, New York, United States (Recruiting)
- Gibbs Cancer Research, Spartanburg Regional Healthcare System — Spartanburg, South Carolina, United States (Recruiting)
- Methodist Digestive Institute — Dallas, Texas, United States (Recruiting)
- McGill University — Montreal, Quebec, Canada (Recruiting)
- Sanno Hospital — Tokyo, Japan, Japan (Recruiting)
- Centro Medico — Mexico City, Mexico (Recruiting)
- National Taiwan University — Taipei, Taiwan (Recruiting)
- Freeman Hospital — High Heaton, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Robert Martin, MD, PhD — University of Louisville
- Study coordinator: Robert Martin, MD, PhD
- Email: robert.martin@louisville.edu
- Phone: 502-629-3355
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.